With Medidata, Dassault to create ‘virtual twins’ of the human body

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Natali_Mis)
(Image: Getty/Natali_Mis)

Related tags: Medidata, Dassault Systèmes

Dassault Systèmes’s $5.8bn acquisition of Medidata is complete – opening up ‘a new world of virtual twin experiences’ for health care, according to the French software firm.

Dassault Systèmes last week completed its acquisition of Medidata. As per the agreement, initially announced in June of this year​, Dassault acquired all of Medidata’s issued and outstanding common shares for $92.25 per share in cash – a total enterprise value of approximately $5.8bn.

In the month following, Dassault announced that its Living Heart Project​ was moving forward with an in silico​ clinical trial underway and plans to evaluate the use of virtual patients as part of a five-year contact with the US Food and Drug Administration (FDA).

“The virtual world will push the bounds of possibilities to transform not only research and science, but also the entire pharmaceutical and medical device industry and medicine, in general. We made virtual twins of cars and airplanes possible. We will do the same for the human body,”​ said Bernard Charlès, vice chairman and CEO of Dassault Systèmes, in a statement addressing the completed transaction.

Dassault Systèmes’ ‘3DExperience platform’ combines modeling, simulation, data science, and artificial intelligence (AI).

“By combining data intelligence and simulation, we power smarter therapeutics for healthier people,” ​added Charlès. “The inclusive and multi-discipline 3DExperience platform will be key for health care innovators to anticipate and address the needs of the industry’s transformation toward affordable precision health care in the 21st century,”

The France-based company described the integration of Medidata as ‘rapid.’ With the deal now complete, Medidata is operating as a Dassault brand, boosting the company’s life sciences business to become its second-largest unit, after transportation and mobility.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us


View more